A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. (Q54567693)

1 June 2018

title

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. (English)

1 reference

1 June 2018

1 reference

2

1 reference

1 June 2018

Javier Martinez-Picado

15

1 reference

1 June 2018

Jens Lundgren

Jens Lundgren

13

0 references

Bonaventura Clotet Sala

12

Bonaventura Clotet

1 reference

1 June 2018

16

EuroSIDA Study Group

1 reference

1 June 2018

Wendy P Bannister

3

Wendy Bannister

1 reference

1 June 2018

Panagiotis Gargalianos

10

Panagiotis Gargalianos

1 reference

1 June 2018

Dénes Bánhegyi

11

Dénes Bánhegyi

1 reference

1 June 2018

Alessandro Cozzi-Lepri

5

Alessandro Cozzi-Lepri

1 reference

1 June 2018

author name string

Roger Paredes

1

1 reference

1 June 2018

Mónica Kisic

4

1 reference

1 June 2018

Christian Pou

6

1 reference

1 June 2018

Rocío Bellido

7

1 reference

1 June 2018

Gilberto Betancor

8

1 reference

1 June 2018

Johannes Bogner

9

1 reference

1 June 2018

Luis Menéndez-Arias

14

1 reference

1 June 2018

language of work or name

English

0 references

publication date

1 September 2011

1 reference

1 June 2018

Journal of Infectious Diseases

published in

1 reference

1 June 2018

volume

204

1 reference

1 June 2018

issue

5

1 reference

1 June 2018

page(s)

741-752

1 reference

1 June 2018

Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Web resources for HIV type 1 genotypic-resistance test interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by alpha-phosphate-modified thymidine analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Studies on the effects of truncating alpha-helix E' of p66 human immunodeficiency virus type 1 reverse transcriptase on template-primer binding and fidelity of DNA synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Human immunodeficiency virus reverse transcriptase and protease sequence database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR385

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIR385

1 reference

1 June 2018

release_de2pxgymmfeexnimrcenmzyn4a

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/de2pxgymmfeexnimrcenmzyn4a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

1 June 2018